[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @ByMadeleineA Madeleine Armstrong Madeleine Armstrong posts on X about $azn, $dsnky, $pfe, $gild the most. They currently have XXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours. ### Engagements: XXXXX [#](/creator/twitter::14673628/interactions)  - X Week XXXXXX +1,268% - X Month XXXXXX +477% - X Months XXXXXXX -XX% - X Year XXXXXXX -XX% ### Mentions: XX [#](/creator/twitter::14673628/posts_active)  - X Week XX +146% - X Month XX +100% - X Months XXX -XX% - X Year XXX +22% ### Followers: XXXXX [#](/creator/twitter::14673628/followers)  - X Week XXXXX +0.46% - X Month XXXXX +0.76% - X Months XXXXX +2.70% - X Year XXXXX +4.90% ### CreatorRank: XXXXXXXXX [#](/creator/twitter::14673628/influencer_rank)  ### Social Influence [#](/creator/twitter::14673628/influence) --- **Social category influence** [stocks](/list/stocks) XXXXX% [currencies](/list/currencies) XXXXX% **Social topic influence** [$azn](/topic/$azn) #47, [$dsnky](/topic/$dsnky) #1, [$pfe](/topic/$pfe) #273, [$gild](/topic/$gild) #24, [$dskny](/topic/$dskny) #1, [$exel](/topic/$exel) #22, [$jnj](/topic/$jnj) #59, [$mrk](/topic/$mrk) #27, [$arvn](/topic/$arvn) 4.35%, [$lly](/topic/$lly) XXXX% **Top accounts mentioned or mentioned by** [@apexonco](/creator/undefined) [@evaluatevantage](/creator/undefined) [@jacobplieth](/creator/undefined) [@jacobplieths](/creator/undefined) [@sanctuarybio](/creator/undefined) [@savoryseaw50174](/creator/undefined) [@sanctuary_bio](/creator/undefined) [@biotwit1](/creator/undefined) [@financebully](/creator/undefined) [@ksaraholland](/creator/undefined) [@houndcl](/creator/undefined) [@biotechch](/creator/undefined) [@anthonystaj](/creator/undefined) **Top assets mentioned** [AstraZeneca PLC (AZN)](/topic/$azn) [Pfizer, Inc. (PFE)](/topic/$pfe) [Gilead Sciences, Inc. (GILD)](/topic/$gild) [Exelixis Inc (EXEL)](/topic/$exel) [Johnson & Johnson (JNJ)](/topic/$jnj) [Merck & Co., Inc. (MRK)](/topic/$mrk) [Arvinas, Inc (ARVN)](/topic/$arvn) [Eli Lilly and Company (LLY)](/topic/$lly) [Novartis AG (NVS)](/topic/$nvs) [Revolution Medicines, Inc. Common Stock (RVMD)](/topic/$rvmd) ### Top Social Posts [#](/creator/twitter::14673628/posts) --- Top posts by engagements in the last XX hours "We were right about Tropion-Breast02 $AZN #ESMO25" [X Link](https://x.com/ByMadeleineA/status/1977658659653226681) [@ByMadeleineA](/creator/x/ByMadeleineA) 2025-10-13T08:52Z 8094 followers, 5283 engagements "Cross-trial comparison of Datroway vs Trodelvy in first-line TNBC at #ESMO25. $AZN & $DSNKY have the edge over $GILD (OS data immature with Trodelvy)" [X Link](https://x.com/ByMadeleineA/status/1979802489672319468) [@ByMadeleineA](/creator/x/ByMadeleineA) 2025-10-19T06:51Z 8093 followers, 5665 engagements "Responses across cancer types and in PDAC with $INCY's KRAS G12D inhibitor at #ESMO25" [X Link](https://x.com/ByMadeleineA/status/1979899579051938126) [@ByMadeleineA](/creator/x/ByMadeleineA) 2025-10-19T13:16Z 8093 followers, 2420 engagements "Adverse events in Stellar-303. Is this really safer than Cabo $EXEL #ESMO25" [X Link](https://x.com/ByMadeleineA/status/1980168229755801658) [@ByMadeleineA](/creator/x/ByMadeleineA) 2025-10-20T07:04Z 8093 followers, 2843 engagements "Carvykti is nearly a blockbuster: $963m in sales in FY 2024 ($334m in Q4 ) $JNJ $LEGN" [X Link](https://x.com/ByMadeleineA/status/1882039390433923332) [@ByMadeleineA](/creator/x/ByMadeleineA) 2025-01-22T12:15Z 8094 followers, 10.6K engagements "Enhertus perioperative Destiny beckons but watch out for ILD. The @ApexOnco take on Destiny-Breast05 & Destiny-Breast11 data at #ESMO25 $AZN $DSKNY" [X Link](https://x.com/ByMadeleineA/status/1979604977753460771) [@ByMadeleineA](/creator/x/ByMadeleineA) 2025-10-18T17:46Z 8094 followers, 3044 engagements "The #ESMO25 discussant Dr Ana Garrido-Castro weighs in on how to choose between Trodelvy & Datroway" [X Link](https://x.com/ByMadeleineA/status/1979819710893138065) [@ByMadeleineA](/creator/x/ByMadeleineA) 2025-10-19T07:59Z 8094 followers, 1183 engagements "$JNJ sees early promise with Rybrevant in relapsed head & neck cancer and is planning a phase X first-line trial. I spoke to the company ahead of #ESMO25 for @ApexOnco" [X Link](https://x.com/ByMadeleineA/status/1979918916836012310) [@ByMadeleineA](/creator/x/ByMadeleineA) 2025-10-19T14:33Z 8093 followers, 18K engagements "$AZN gives the PDUFA date for Enhertu + Perjeta in 1st-line HER2+ve as "Q1 2026" but $DSKNY is more specific: XX Jan (use based on Destiny-Breast09)" [X Link](https://x.com/ByMadeleineA/status/1970769069206052892) [@ByMadeleineA](/creator/x/ByMadeleineA) 2025-09-24T08:35Z 8093 followers, 2952 engagements "Compare the wording on OS from $AZN & $DSKNY on Tropion-Breast02 vs $GILD on Ascent-03. Datroway "stat sig & clinically meaningful" on both PFS & OS but only "no OS detriment" for Trodelvy" [X Link](https://x.com/ByMadeleineA/status/1975114941582717427) [@ByMadeleineA](/creator/x/ByMadeleineA) 2025-10-06T08:24Z 8094 followers, 9393 engagements "PFS curves with Trodelvy in Ascent-03 $GILD #ESMO25" [X Link](https://x.com/ByMadeleineA/status/1979810648436687097) [@ByMadeleineA](/creator/x/ByMadeleineA) 2025-10-19T07:23Z 8093 followers, XXX engagements "Missed this at the time of the presentation as footnote is so small: X gr3 pneumonitis then death in Tropion-Breast02 was deemed related to disease $AZN $DSNKY #ESMO25" [X Link](https://x.com/ByMadeleineA/status/1979846122308026423) [@ByMadeleineA](/creator/x/ByMadeleineA) 2025-10-19T09:44Z 8093 followers, 4055 engagements "Response rates with Ralu-dxd at #ESMO25 XX% ORR across doses $MRK $DSNKY" [X Link](https://x.com/ByMadeleineA/status/1979909635105546372) [@ByMadeleineA](/creator/x/ByMadeleineA) 2025-10-19T13:56Z 8093 followers, 20.2K engagements "German Merck's #ESMO25 booth. Well that's one way to wake yourself up on a tired Monday morning" [X Link](https://x.com/ByMadeleineA/status/1980171041654874169) [@ByMadeleineA](/creator/x/ByMadeleineA) 2025-10-20T07:15Z 8093 followers, 2362 engagements "$PFE jumps straight from phase X to phase X with its EZH2 inhibitor mevrometostat. What could possibly go wrong Via @ApexOnco $IPN.PA $DSNKY $NVS" [X Link](https://x.com/ByMadeleineA/status/1825509871296364953) [@ByMadeleineA](/creator/x/ByMadeleineA) 2024-08-19T12:27Z 8093 followers, 5572 engagements "#ESMO24 presentation on $ALPMY's KRAS G12D degrader zooms in on PDAC & NSCLC pts. Favourable vs the overall X% ORR across the trial in the abstract but small pt numbers involved" [X Link](https://x.com/ByMadeleineA/status/1835304095441211644) [@ByMadeleineA](/creator/x/ByMadeleineA) 2024-09-15T13:06Z 8094 followers, 13.4K engagements "$RVMD shows selective KRAS G12D promise at #Enasymp24. My take via @ApexOnco $ALPMY" [X Link](https://x.com/ByMadeleineA/status/1850891989446721772) [@ByMadeleineA](/creator/x/ByMadeleineA) 2024-10-28T13:26Z 8092 followers, 4352 engagements "$EXEL stops Stellar-305 trial of zanzalintinib. My most recent take on this asset via @ApexOnco" [X Link](https://x.com/ByMadeleineA/status/1950104406193484178) [@ByMadeleineA](/creator/x/ByMadeleineA) 2025-07-29T08:01Z 8094 followers, 2042 engagements "$RHHY is out with oral SERD data ahead of its #ESMO25 presentation. The ITT result looks clearly driven by ESR1m pts; the question now is whether Roche has done enough to get a broad label $LLY $ARVN $PFE" [X Link](https://x.com/ByMadeleineA/status/1979417010497872017) [@ByMadeleineA](/creator/x/ByMadeleineA) 2025-10-18T05:19Z 8095 followers, 4793 engagements "Well these are the most promising signs I think we've seen in non-ESR1m pts with a SERD. And $RHHBY has been clever by enrolling XX% of pts in Evera with ESR1m. Now over to the FDA #ESMO25 $LLY $PFE $ARVN" [X Link](https://x.com/ByMadeleineA/status/1979466325064880363) [@ByMadeleineA](/creator/x/ByMadeleineA) 2025-10-18T08:35Z 8094 followers, 1819 engagements "Padcev plus Keytruda sets the perioperative bladder cancer bar at #ESMO25 $PFE $ALPMF $MRK" [X Link](https://x.com/ByMadeleineA/status/1979599881590153668) [@ByMadeleineA](/creator/x/ByMadeleineA) 2025-10-18T17:26Z 8094 followers, 1810 engagements "More info on Stellar-303 deaths #ESMO25" [X Link](https://x.com/ByMadeleineA/status/1980177020958204101) [@ByMadeleineA](/creator/x/ByMadeleineA) 2025-10-20T07:39Z 8094 followers, 1056 engagements "@Sanctuary_Bio For a moment I thought you were talking about the Merck stand" [X Link](https://x.com/ByMadeleineA/status/1980181781568442432) [@ByMadeleineA](/creator/x/ByMadeleineA) 2025-10-20T07:58Z 8094 followers, XXX engagements "More info needed on $EXEL's Cabometyx follow-on zanzalintinib in colorectal cancer the #ESMO25 discussant says" [X Link](https://x.com/ByMadeleineA/status/1980211479485022714) [@ByMadeleineA](/creator/x/ByMadeleineA) 2025-10-20T09:56Z 8094 followers, 1323 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@ByMadeleineA Madeleine Armstrong
Madeleine Armstrong posts on X about $azn, $dsnky, $pfe, $gild the most. They currently have XXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours.
Engagements: XXXXX #
- X Week XXXXXX +1,268%
- X Month XXXXXX +477%
- X Months XXXXXXX -XX%
- X Year XXXXXXX -XX%
Mentions: XX #
- X Week XX +146%
- X Month XX +100%
- X Months XXX -XX%
- X Year XXX +22%
Followers: XXXXX #
- X Week XXXXX +0.46%
- X Month XXXXX +0.76%
- X Months XXXXX +2.70%
- X Year XXXXX +4.90%
CreatorRank: XXXXXXXXX #
Social Influence #
Social category influence stocks XXXXX% currencies XXXXX%
Social topic influence $azn #47, $dsnky #1, $pfe #273, $gild #24, $dskny #1, $exel #22, $jnj #59, $mrk #27, $arvn 4.35%, $lly XXXX%
Top accounts mentioned or mentioned by @apexonco @evaluatevantage @jacobplieth @jacobplieths @sanctuarybio @savoryseaw50174 @sanctuary_bio @biotwit1 @financebully @ksaraholland @houndcl @biotechch @anthonystaj
Top assets mentioned AstraZeneca PLC (AZN) Pfizer, Inc. (PFE) Gilead Sciences, Inc. (GILD) Exelixis Inc (EXEL) Johnson & Johnson (JNJ) Merck & Co., Inc. (MRK) Arvinas, Inc (ARVN) Eli Lilly and Company (LLY) Novartis AG (NVS) Revolution Medicines, Inc. Common Stock (RVMD)
Top Social Posts #
Top posts by engagements in the last XX hours
"We were right about Tropion-Breast02 $AZN #ESMO25"
X Link @ByMadeleineA 2025-10-13T08:52Z 8094 followers, 5283 engagements
"Cross-trial comparison of Datroway vs Trodelvy in first-line TNBC at #ESMO25. $AZN & $DSNKY have the edge over $GILD (OS data immature with Trodelvy)"
X Link @ByMadeleineA 2025-10-19T06:51Z 8093 followers, 5665 engagements
"Responses across cancer types and in PDAC with $INCY's KRAS G12D inhibitor at #ESMO25"
X Link @ByMadeleineA 2025-10-19T13:16Z 8093 followers, 2420 engagements
"Adverse events in Stellar-303. Is this really safer than Cabo $EXEL #ESMO25"
X Link @ByMadeleineA 2025-10-20T07:04Z 8093 followers, 2843 engagements
"Carvykti is nearly a blockbuster: $963m in sales in FY 2024 ($334m in Q4 ) $JNJ $LEGN"
X Link @ByMadeleineA 2025-01-22T12:15Z 8094 followers, 10.6K engagements
"Enhertus perioperative Destiny beckons but watch out for ILD. The @ApexOnco take on Destiny-Breast05 & Destiny-Breast11 data at #ESMO25 $AZN $DSKNY"
X Link @ByMadeleineA 2025-10-18T17:46Z 8094 followers, 3044 engagements
"The #ESMO25 discussant Dr Ana Garrido-Castro weighs in on how to choose between Trodelvy & Datroway"
X Link @ByMadeleineA 2025-10-19T07:59Z 8094 followers, 1183 engagements
"$JNJ sees early promise with Rybrevant in relapsed head & neck cancer and is planning a phase X first-line trial. I spoke to the company ahead of #ESMO25 for @ApexOnco"
X Link @ByMadeleineA 2025-10-19T14:33Z 8093 followers, 18K engagements
"$AZN gives the PDUFA date for Enhertu + Perjeta in 1st-line HER2+ve as "Q1 2026" but $DSKNY is more specific: XX Jan (use based on Destiny-Breast09)"
X Link @ByMadeleineA 2025-09-24T08:35Z 8093 followers, 2952 engagements
"Compare the wording on OS from $AZN & $DSKNY on Tropion-Breast02 vs $GILD on Ascent-03. Datroway "stat sig & clinically meaningful" on both PFS & OS but only "no OS detriment" for Trodelvy"
X Link @ByMadeleineA 2025-10-06T08:24Z 8094 followers, 9393 engagements
"PFS curves with Trodelvy in Ascent-03 $GILD #ESMO25"
X Link @ByMadeleineA 2025-10-19T07:23Z 8093 followers, XXX engagements
"Missed this at the time of the presentation as footnote is so small: X gr3 pneumonitis then death in Tropion-Breast02 was deemed related to disease $AZN $DSNKY #ESMO25"
X Link @ByMadeleineA 2025-10-19T09:44Z 8093 followers, 4055 engagements
"Response rates with Ralu-dxd at #ESMO25 XX% ORR across doses $MRK $DSNKY"
X Link @ByMadeleineA 2025-10-19T13:56Z 8093 followers, 20.2K engagements
"German Merck's #ESMO25 booth. Well that's one way to wake yourself up on a tired Monday morning"
X Link @ByMadeleineA 2025-10-20T07:15Z 8093 followers, 2362 engagements
"$PFE jumps straight from phase X to phase X with its EZH2 inhibitor mevrometostat. What could possibly go wrong Via @ApexOnco $IPN.PA $DSNKY $NVS"
X Link @ByMadeleineA 2024-08-19T12:27Z 8093 followers, 5572 engagements
"#ESMO24 presentation on $ALPMY's KRAS G12D degrader zooms in on PDAC & NSCLC pts. Favourable vs the overall X% ORR across the trial in the abstract but small pt numbers involved"
X Link @ByMadeleineA 2024-09-15T13:06Z 8094 followers, 13.4K engagements
"$RVMD shows selective KRAS G12D promise at #Enasymp24. My take via @ApexOnco $ALPMY"
X Link @ByMadeleineA 2024-10-28T13:26Z 8092 followers, 4352 engagements
"$EXEL stops Stellar-305 trial of zanzalintinib. My most recent take on this asset via @ApexOnco"
X Link @ByMadeleineA 2025-07-29T08:01Z 8094 followers, 2042 engagements
"$RHHY is out with oral SERD data ahead of its #ESMO25 presentation. The ITT result looks clearly driven by ESR1m pts; the question now is whether Roche has done enough to get a broad label $LLY $ARVN $PFE"
X Link @ByMadeleineA 2025-10-18T05:19Z 8095 followers, 4793 engagements
"Well these are the most promising signs I think we've seen in non-ESR1m pts with a SERD. And $RHHBY has been clever by enrolling XX% of pts in Evera with ESR1m. Now over to the FDA #ESMO25 $LLY $PFE $ARVN"
X Link @ByMadeleineA 2025-10-18T08:35Z 8094 followers, 1819 engagements
"Padcev plus Keytruda sets the perioperative bladder cancer bar at #ESMO25 $PFE $ALPMF $MRK"
X Link @ByMadeleineA 2025-10-18T17:26Z 8094 followers, 1810 engagements
"More info on Stellar-303 deaths #ESMO25"
X Link @ByMadeleineA 2025-10-20T07:39Z 8094 followers, 1056 engagements
"@Sanctuary_Bio For a moment I thought you were talking about the Merck stand"
X Link @ByMadeleineA 2025-10-20T07:58Z 8094 followers, XXX engagements
"More info needed on $EXEL's Cabometyx follow-on zanzalintinib in colorectal cancer the #ESMO25 discussant says"
X Link @ByMadeleineA 2025-10-20T09:56Z 8094 followers, 1323 engagements